Tier 2 — strong

Adjunctive berberine for schizophrenia with metabolic syndrome: a systematic review and meta-analysis

Xie K, Tian W, Zhang Y, Zhang Y, Li J, Cao D, Pan W

Frontiers in psychiatry 2026 17:1846995

Bibliography

PubMed: PMID 42433212
PubMed Central: PMC13352474
DOI: 10.3389/fpsyt.2026.1846995
Funding: Funding was not established from the accessible source; this is not a declaration of no funding.
Competing interests: The authors declared no competing interests in the publication.

Design	Systematic review and meta-analysis
Model	Published human studies
Sample	3 randomized trials; 233 participants
Intervention	Evidence synthesis; interventions and comparators vary across included studies
Duration	No new treatment; included-study durations vary
Endpoints	Pooled clinical or metabolic outcomes; Risk of bias and heterogeneity; Adverse-event reporting

Adjunctive treatment improved several weight and metabolic measures, but LDL, HDL, HbA1c and blood-pressure differences were not significant.

Adjunctive treatment improved several weight and metabolic measures, but LDL, HDL, HbA1c and blood-pressure differences were not significant.

Few trials and possible companion reporting in this field; no general psychiatric-treatment or obesity claim follows.

Editorial review

Last verified 22 October 2026